#Chicago #ASCO22 Conquering cancer.

Everolimus (mTor inh) like most TKIs, fail to significantly improve RFS/DFS in RCC adjuvant setting. Hope ICIs will show OS improvement in the near future. #ASCO22 #KCSM #EVEREST

#CBM588 decreases antibiotic resistance genes resulting in better response to ICIs. Another move forward in tailoring #cancer treatment. #ASCO22 #KCSM

Neoadjuvant dostarlimab (anti PD-1) resulted in 100% clinical CR in 12 patients with MMRd stage II/III Rectal cancer. Small cohort and relatively short follow up, yet looks promising 👌🏽. #ASCO22 #CRCSM

Wrapping up #ASCO22, here’s my starting 5 across all tracks: Tdx in HER2-low mBC, Dostarlimab in Rectal ca, ctDNA in Adj CRC and HER2- breast, Lu-177 in mCRPC, ADCs incorporated almost in all fields. Revolution is alive. #Destiny #Breast04 #DYNAMIC #CHiRP #VISION #TheraP #ADC

Very informative work from our Dana-Farber Lank Center for Genitourinary Oncology and Dana-Farber colleague Misha Beltran and her team + #DeBono’s team on how to target the prostate cancer #surfacome Balaji Nature Portfolio nature.com/articles/s4158…

Collaborative efforts are necessary to improve MENA representation in future oncology research. #MENA #ClinicalTrials #Oncology

#MCCRWorkshop Faculty & Fellows, class of 2025! Since 1999, this workshop has fostered innovation, collaboration, and groundbreaking research in clinical cancer. #EORTC ESMO - Eur. Oncology AACR

Excellent teamwork. ICIs should likely be administered early in the treatment of MMRd prostate cancers.

Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study sciencedirect.com/science/articl… This multicenter, retrospective study evaluated the real-world efficacy of first-line immune-based combinations in 323

To keep barca more than a club. #CiaoBarto